Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Press ReleaseNicox Provides Third Quarter 2024 update and First Half 2024 Financial Results  Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3 2025Cash of €19.7 million on September 30, 2024, including the estimated net proceeds of the VYZULTA royalty sale and equity investment announced on October 14, 2024The Company estimates that it is financed into Q3 2025October 17, 2024 – release at 7:30 am CETSophia...

Biot, 17/10/2024 (informazione.it - comunicati stampa - salute e benessere)

Income Statement

Balance sheet

 

Net revenue consists of revenue from collaborations less royalty payments

Attachment